Hematology Update - Fall 2017
ACUTE MYELOID LEUKEMIA – NEWLY DIAGNOSED
DCSK1916. Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients with Newly Diiagnosed FLT3-ITD(+) AML
clinicaltrials.gov #NCT02668653
Local PI: Brenda Cooper, MD
GSI1916. Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia
clinicaltrials.gov #NCT02343939
Local PI: Benjamin Tomlinson, MD
HLSN1917. A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients ?18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy
clinicaltrials.gov # NCT03151408
Local PI: Brenda Cooper, MD
UCCC1915. Nivolumab in Eliminating Minima Residual Disease and Preventing Relapse in Patients with Acute Myeloid Leukemia in Remission after Chemotherapy (MAINTENANCE THERAPY TRIAL)
clinicaltrials.gov #NCT02275533
Local PI: Brenda Cooper, MD
RELAPSED ACUTE LEUKEMIAS OR MDS
DFCI1917. A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
clinicaltrials.gov #NCT02890329
Local PI: Benjamin Tomlinson, MD
AGLA1916. A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients with AML or MDS
clinicaltrials.gov #NCT02732184
Local PI: Benjamin Tomlinson, MD
ADCT1916. Study of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
clinicaltrials.gov #NCT02669264
Local PI: Benjamin Tomlinson, MD
NOVEL ALLOGENEIC STEM CELL TRANSPLANT FOR ACUTE LEUKEMIAS
ACTN1916. Study of Iomab-B Prior to Hematopoietic Stem Cell Transplant Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory AML.
clinicaltrials.gov #NCT02129582
Local PI: Benjamin Tomlinson, MD
CASE9Z13. Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients with Hematologic Malignancies
clinicaltrials.gov #NCT02129582
Local PI: Paolo Caimi, MD
CASE1916. Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
clinicaltrials.gov #NCT03104491
Local PI: Leland Metheny, MD